Lexaria Bioscience (LEXX) is a CA-listed Healthcare company in Biotechnology with a market capitalization of
2M, trading at $0.58 on the NASDAQ. This SniperIQ fundamentals page covers Lexaria Bioscience's valuation, profitability (net margin -3985.6%), revenue ($705,923 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
2M
Net Margin-3985.6%
Revenue (FY25)$705,923
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Lexaria Bioscience's market cap?
Lexaria Bioscience (LEXX) has a market capitalization of approximately
2M, trading at $0.58 on the NASDAQ. Market cap moves with the live share price.
What is Lexaria Bioscience's P/E ratio?
Lexaria Bioscience's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lexaria Bioscience?
Lexaria Bioscience runs a net profit margin of -3985.6%, a gross margin of 100.0%, and an operating margin of -3973.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lexaria Bioscience generate?
Lexaria Bioscience reported revenue of $705,923 for fiscal year 2025, with net income of -
2M and earnings per share (EPS) of -0.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lexaria Bioscience pay a dividend?
Lexaria Bioscience does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Lexaria Bioscience financially healthy?
Lexaria Bioscience carries a debt-to-equity ratio of 0.02x and a current ratio of 10.60x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lexaria Bioscience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lexaria Bioscience (LEXX) the key facts are: market cap
2M, revenue $705,923, 52-week range 0.46-1.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lexaria Bioscience's full fundamentals live
Get Lexaria Bioscience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.